Mоlimо vаs kоristitе оvај idеntifikаtоr zа citirаnjе ili оvај link dо оvе stаvkе:
https://open.uns.ac.rs/handle/123456789/32459
Nаziv: | Pharmacological and Advanced Cell Respiration E ects, Enhanced by Toxic Human-Bile Nano-Pharmaceuticals of Probucol Cell-Targeting Formulations | Аutоri: | Susbin Raj Wagle Božica Kovačević Daniel Walker Corina Mihaela Ionescu Melissa Jones Goran Stojanović Sanja Kojić Armin Mooranian Hani Al-Salami |
Ključnе rеči: | bile acids;diabetes mellitus;formulation sciences;Inflammation;probucol;unconjugated lithocholic acid | Dаtum izdаvаnjа: | 29-јул-2020 | Izdаvаč: | MDPI | Prојеkаt: | H2020 SALSETH | Čаsоpis: | Pharmaceutics | Sažetak: | Bile acids have recently been studied for potential applications as formulation excipients and enhancers for drug release; however, some bile acids are not suitable for this application. Unconjugated lithocholic acid (ULCA) has recently shown drug formulation-stabilizing and anti-inflammatory effects. Lipophilic drugs have poor gut absorption after an oral dose, which necessitates the administration of high doses and causes subsequent side effects. Probucol (PB) is a highly lipophilic drug with poor oral absorption that resulted in restrictions on its clinical prescribing. Hence, this study aimed to design new delivery systems for PB using ULCA-based matrices and to test drugformulation, release, temperature, and biological effects. ULCA-based matrices were formulated for PB oral delivery by applying the jet-flow microencapsulation technique using sodium alginate as a polymer. ULCA addition to new PB matrices improved the microcapsule’s stability, drug release in vitro (formulation study), and showed a promising effect in ex vivo study (p < 0.05), suggesting that ULCA can optimize the oral delivery of PB and support its potential application in diabetes treatment. | URI: | https://open.uns.ac.rs/handle/123456789/32459 | ISSN: | 1999-4923 | DOI: | 10.3390/pharmaceutics12080708 | Prаvа: | Attribution-NonCommercial-NoDerivs 3.0 United States |
Nаlаzi sе u kоlеkciјаmа: | FTN Publikacije/Publications |
Dаtоtеkе u оvој stаvci:
Dаtоtеkа | Оpis | Vеličinа | Fоrmаt | |
---|---|---|---|---|
pharmaceutics-12-00708.pdf | 1.64 MB | Adobe PDF | Pоglеdајtе |
Prеglеd/i stаnicа
30
Prоtеklа nеdеljа
4
4
Prоtеkli mеsеc
0
0
prоvеrеnо 10.05.2024.
Prеuzimаnjе/а
14
prоvеrеnо 10.05.2024.
Google ScholarTM
Prоvеritе
Аlt mеtrikа
Оvа stаvkа је licеncirаnа pоd Krеаtivnа dоzvоlа grаđаnа